MINDCURE's President and CEO, Kelsey Ramsden updates investors on iSTRYM's launch and rapid penetration, as well as drug development news on several fronts.
MINDCURE's President and CEO, Kelsey Ramsden updates investors on iSTRYM's launch and rapid penetration, as well as drug development news on several fronts.
As MINDCURE's iSTRYM digital therapeutics platform rapidly gathers momentum, the company looks poised to join the emerging rally in the sector.
Mind Cure Health Inc., is pleased to provide an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology.
Compass Pathways lifted the whole sector in 2020. With CMPS again rising, is history about to repeat?
The rapidly expanding networks of psychedelics-based treatment clinics is a horse race where EVERYONE is a winner.
Psychedelic drugs are all over the news. Not just general news but also business media. Big news. Big Business.
Cash-rich psychedelic stocks are cheap. They are also building value for investors -- at an accelerating rate.
Drug development through the formal clinical trials process is slow and expensive. Real World Evidence (RWE) drug development is fast and cheap. Have we got your attention yet?
The "crippling labor shortages" plaguing the U.S. economy are directly attributable to the Mental Health Crisis. Psychedelic medicine is the only answer.
Psychedelic stocks today are cash-rich with extremely attractive valuations. Blue-chip stocks sit with record debt levels and grossly inflated valuations. Advantage: psychedelic stocks.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now